Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: A meta-analysis of randomized trials

American Heart Journal

Volumn 162, Issue 1, 2011, Pages

  Berger, Jeffrey S ^a   Lala, Anuradha ^a   Krantz, Mori J ^b,c   Baker, Gizelle S ^d   Hiatt, William R ^b,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c University of Colorado ^*  (United States)

^d Global Health and Health Disparities   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO;

AGE; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GENDER; HEART DEATH; HEART INFARCTION; HUMAN; META ANALYSIS; PRIORITY JOURNAL; STROKE;

EID: 79960200973     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2011.04.006     Document Type: Article

References (45)

1. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ (Clin Res ed) 324 2002 71 86
2. J.S. Berger, D.L. Brown, and R.C. Becker Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis Am J Med 121 2008 43 49
3. C. Patrono, C. Baigent, and J. Hirsh Antiplatelet drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition) Chest 133 2008 199S 233S (Pubitemid 351894914)
4. S.C. Smith Jr., J. Allen, and S.N. Blair AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute Circulation 113 2006 2363 2372 (Pubitemid 43947981)
5. E.M. Antman, M. Hand, and P.W. Armstrong 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 writing group to review new evidence and update the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction, writing on behalf of the 2004 writing committee Circulation 117 2008 296 329
6. J.L. Anderson, C.D. Adams, and E.M. Antman ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine Circulation 116 2007 e148 e304
7. S. Juul-Moller, N. Edvardsson, and B. Jahnmatz Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) group Lancet 340 1992 1421 1425
8. The SALT Collaborative Group Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events Lancet 338 1991 1345 1349
9. B. Farrell, J. Godwin, and S. Richards The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results J Neurol Neurosurg Psychiatry 54 1991 1044 1054
10. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2 Lancet 2 1988 349 360
11. H.D. Lewis Jr., J.W. Davis, and D.G. Archibald Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study N Engl J Med 309 1983 396 403 (Pubitemid 13033964)
12. L.C. Wallentin Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast Sweden J Am Coll Cardiol 18 1991 1587 1593
13. Z.M. Chen, P. Sandercock, and H.C. Pan Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40 000 randomized patients from the Chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups Stroke 31 2000 1240 1249 (Pubitemid 30351240)
14. M.J. Krantz, J.S. Berger, and W.R. Hiatt An aspirin a day: are we barking up the wrong willow tree? Pharmacotherapy 30 2010 115 118
15. J.S. Berger Aspirin as preventive therapy in patients with asymptomatic vascular disease JAMA 303 2010 880 882
16. Cardiovascular and Renal Drugs Advisory Committee. Available at: http://www.fda.gov/ohrms/DOCKETS/ac/03/questions/4012Q1-Final.pdf. Last accessed on March 13, 2010.
17. C. Baigent, L. Blackwell, and R. Collins Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 373 2009 1849 1860
18. J.S. Berger, M.C. Roncaglioni, and F. Avanzini Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials JAMA 295 2006 306 313
19. J. Belch, A. MacCuish, and I. Campbell The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease BMJ (Clin Res ed.) 337 2008 a1840
20. F.G. Fowkes, J.F. Price, and M.C.W. Stewart Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index JAMA 303 2010 841 848
21. H. Ogawa, M. Nakayama, and T. Morimoto Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial JAMA 300 2008 2134 2141
22. L. Hansson, A. Zanchetti, and S.G. Carruthers Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group Lancet 351 1998 1755 1762 (Pubitemid 28269185)
23. The Medical Research Council's General Practice Research Framework Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk Lancet 351 1998 233 241
24. R. Peto, R. Gray, and R. Collins Randomised trial of prophylactic daily aspirin in British male doctors Br Med J (Clin Res ed.) 296 1988 313 316 (Pubitemid 18042841)
25. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group N Engl J Med 321 1989 129 135
26. P.M. Ridker, N.R. Cook, and I.M. Lee A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women N Engl J Med 352 2005 1293 1304
27. G. De Berardis, M. Sacco, and G.F. Strippoli Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials BMJ (Clin Res ed. 339 2009 b4531
28. J.S. Berger, M.J. Krantz, and J.M. Kittelson Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials JAMA 301 2009 1909 1919
29. E.S. Ford, U.A. Ajani, and J.B. Croft Explaining the decrease in U.S. deaths from coronary disease, 1980-2000 N Engl J Med 356 2007 2388 2398 (Pubitemid 46883773)
30. M.G. Hunink, L. Goldman, and A.N. Tosteson The recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatment JAMA 277 1997 535 542 (Pubitemid 27083982)
31. J.S. Berger, C.O. Jordan, and D. Lloyd-Jones Screening for cardiovascular risk in asymptomatic patients J Am Coll Cardiol 55 2010 1169 1177
32. F.G. Fowkes, G.D. Murray, and I. Butcher Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis JAMA 300 2008 197 208 (Pubitemid 351969304)
33. D.H. O'Leary, J.F. Polak, and R.A. Kronmal Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group N Engl J Med 340 1999 14 22 (Pubitemid 29024679)
34. R.S. Eidelman, P.R. Hebert, and S.M. Weisman An update on aspirin in the primary prevention of cardiovascular disease Arch Intern Med 163 2003 2006 2010 (Pubitemid 37151241)
35. G. de Gaetano Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project Lancet 357 2001 89 95
36. R. Cooper, J. Cutler, and P. Desvigne-Nickens Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention Circulation 102 2000 3137 3147
37. D.L. Bhatt, K.A. Fox, and W. Hacke Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events N Engl J Med 354 2006 1706 1717
38. N. Haramaki, H. Ikeda, and K. Takenaka Fluvastatin alters platelet aggregability in patients with hypercholesterolemia: possible improvement of intraplatelet redox imbalance via HMG-CoA reductase Arterioscler Thromb Vasc Biol 27 2007 1471 1477 (Pubitemid 46809440)
39. J.K. Damas, L. Puccetti, and P. Aukrust Early anti-thrombotic and anti-inflammatory actions of statins and fibrates-time for adjuvant therapy in acute coronary syndromes? Thromb Haemost 94 2005 1 3 (Pubitemid 40974698)
40. J.H. Lee, J.H. O'Keefe, and C.J. Lavie Omega-3 fatty acids: cardiovascular benefits, sources and sustainability Nat Rev Cardiol 6 2009 753 758
41. A. Okrucka, J. Pechan, and H. Kratochvilova Effects of the angiotensin-converting enzyme (ACE) inhibitor perindopril on endothelial and platelet functions in essential hypertension Platelets 9 1998 63 67 (Pubitemid 28105254)
42. L. Moser, K.S. Callahan, and A.K. Cheung ACE inhibitor effects on platelet function in stages I-II hypertension J Cardiovasc Pharmacol 30 1997 461 467 (Pubitemid 27527581)
43. P.J. Barter, and K.A. Rye Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism? Circulation 113 2006 1553 1555 (Pubitemid 43739413)
44. S. Goto Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding Atheroscler Suppl 6 2005 3 11 (Pubitemid 43263084)
45. V.L. Serebruany, A.H. Glassman, and A.I. Malinin Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy Circulation 108 2003 939 944 (Pubitemid 37048222)